

**REDACTION AND CONFIDENTIALITY LOG TO FORM HCMO-1 AND ATTACHMENTS**

<b>BATES REFERENCE</b>	<b>PARTY INFORMATION</b>	<b>INFORMATION REQUESTED</b>	<b>INFORMATION REDACTED</b>	<b>BASIS FOR REDACTION</b>
TRAN_HCMO-0000028 – TRAN_HCMO-000034	Transcarent and Accolade	<u>HCMO-1b – Business Entities Form</u>	EIN Numbers of Entities	<p>The parties request confidential treatment of certain information provided in the HCMO 1-b Form. This information has not been made publicly available in any other forum. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in Transcarent’s operating model. (See ORS 192.345(2)).</p> <p>Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a material change transaction”. As such, the parties are requesting further confidential treatment of these materials.</p>
TRAN_HCMO-000146 – TRAN_HCMO-000155	Accolade and Transcarent	<u>Transaction Documents</u>	Confidentiality Agreement	<p>The Parties request confidential treatment of certain information contained within the Parties’ Confidentiality and Non-Disclosure Agreement (the “NDA”). The information redacted in the NDA qualifies as a “trade secret” under ORS 192.345 in that it is non-public, competitively sensitive information that relates to the parties’ business strategy and is known only by the executives who have certified this filing, their representatives, and the attorneys who have helped prepare the filing. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the companies’ operating models.</p> <p>Pursuant to ORS 415.501(13)(c), the Parties request further confidential treatment of the NDA unless they provide their prior written consent.</p>
TRAN_HCMO-000164 – TRAN_HCMO-000218	Transcarent	<u>Financial Statements</u>	2022 and 2023 Financial Statements	<p>Transcarent requests confidential treatment of the Transcarent Financial Statements. As a nonpublic entity, this information has not been made publicly available in any other forum. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the company's operating model (See ORS 192.345(2)).</p> <p>Under ORS 415.501(13)(c), the Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a material change transaction." As such, Transcarent is requesting further confidential treatment of its Financial Statements, unless Transcarent provides its written consent to publication.</p>

BATES REFERENCE	PARTY INFORMATION	INFORMATION REQUESTED	INFORMATION REDACTED	BASIS FOR REDACTION
TRAN_HCMO-000317 – TRAN_HCMO-000332	Transcarent	<u>Attachment to Section 7(b) of HCMO-1.</u>	Board Presentation Materials	<p>The Board Presentation Materials have not been made publicly available in any other forum, contain highly confidential and sensitive information and relate to Transcarent’s business strategy, they are also a trade secret and can be kept confidential pursuant to ORS 192.345(2). The information contained in the Board Meeting Materials is not available to the public and is only known by the executives of Transcarent and certain advisors.</p> <p>Under ORS 415.501(13)(c), the Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a material change transaction.</p>
TRAN_HCMO-000333 – TRAN_HCMO-000344	Transcarent	<u>Attachment to Section 7(b) of HCMO-1.</u>	Valuation Materials	<p>The Valuation Materials qualify as a trade secret under ORS 192.345(2), as a compilation of competitively sensitive information. Transcarent has spent considerable time and expense in evaluating the transaction and has specifically endeavored not to publicize the Valuation Materials as Transcarent would be materially harmed should they be publicized.</p> <p>Under ORS 415.501(13)(c), the Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a material change transaction. As such, Transcarent requests confidential treatment of the Valuation Materials.</p>
TRAN_HCMO-000345 – TRAN_HCMO-000760	Transcarent	<u>Attachment to Section 9(a) of HCMO-1.</u>	Pre-Merger Notification Filing and Attachments	<p>Transcarent requests confidential treatment of Attachment A (Pre-Merger Notification Filing and Attachments). This information has not been made publicly available in any other forum. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in Transcarent’s operating model. (<i>See</i> ORS 192.345(2)).</p> <p>Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a material change transaction”. As such, Transcarent is requesting further confidential treatment of these materials.</p>
ACC-HCMO-HCR-000001 – ACC-HCMO-HCR-000194	Accolade	<u>Accolade HSR documents provided separately from HCMO-1 filing.</u>	Pre-Merger Notification Filing and Attachments	<p>Accolade requests confidential treatment of its HSR filing and attendant documents submitted separately from the parties’ HCMO-1 filing. This information has not been made publicly available in any other forum. Further, this information is competitively sensitive, and</p>

BATES REFERENCE	PARTY INFORMATION	INFORMATION REQUESTED	INFORMATION REDACTED	BASIS FOR REDACTION
				<p>disclosure would enable competitors to identify and exploit vulnerabilities in Accolade's operating model. (<i>See</i> ORS 192.345(2)).</p> <p>Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a material change transaction". As such, Accolade is requesting further confidential treatment of these materials.</p>
TRAN_HCMO-000783 – TRAN_HCMO-000788	Transcarent	<u>Financial Statements</u>	2021 and 2024 Financial Statements	<p>Transcarent requests confidential treatment of the Transcarent Financial Statements. As a nonpublic entity, this information has not been made publicly available in any other forum. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the company's operating model (<i>See</i> ORS 192.345(2)).</p> <p>Under ORS 415.501(13)(c), the Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a material change transaction." As such, Transcarent is requesting further confidential treatment of its Financial Statements, unless Transcarent provides its written consent to publication.</p>